The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

Two closed-end funds (CEFs) are trading at significant discounts to net asset value due to market concerns about interest rates under new Fed Chair Kevin Warsh's inflation-focused approach. BlackRock Enhanced Equity Dividend Trust (BDJ) offers a 7.8% monthly dividend at a 6.7% discount, while BlackRock Multi-Sector Income Trust (BIT) provides an 11.9% yield at a 6.1% discount. Both funds are positioned to benefit as inflation eases and rates decline, potentially closing their discounts.

The global healthcare services market is projected to grow from USD 8.62 trillion in 2025 to USD 20.10 trillion by 2035, with a CAGR of 8.87%. Growth is driven by rising chronic disease prevalence, aging populations, and digital healthcare adoption including telehealth and AI-enabled care. The U.S. market is expected to reach USD 4.93 trillion and Europe USD 6.25 trillion by 2035. Hospital services will dominate with 44% market share, while telehealth services will experience the fastest growth.

Fluency has issued a retraction notice advising that a previous news release from June 11, 2026, regarding CVS using Fluency to close enterprise AI deployment gaps should be disregarded by journalists and readers.

Autonomize, a healthcare AI company, announced the appointment of three distinguished leaders to its Advisory Board—Dr. Brian Anderson (CEO of Coalition for Health AI), Bill Fandrich (healthcare and financial services executive), and Keith Reynolds (COO of Welldoc)—along with Mike Longacre as Head of Transformation. These appointments aim to help healthcare organizations move beyond AI pilots to enterprise-wide adoption with measurable operational, clinical, and financial impact.

Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a diversified healthcare services company and expected double-digit earnings growth.

Morgan Stanley raised UnitedHealth's price target to $453 from $395 and named it a top pick, citing the company's leadership in AI adoption within managed care. The firm believes AI deployment could drive operational improvements, enhance medical loss ratios, and create new revenue opportunities, with potential for roughly 45% average earnings per share upside as efficiencies scale. UnitedHealth shares were trading near their 52-week high.

CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89% dividend yield significantly exceeds the S&P 500 average, making it an attractive income investment with minimal risk of elimination.

H1, an AI-powered healthcare platform for identifying and engaging physicians, secured a $40M investment led by CVS Health Ventures. The funding follows successful collaborations between the companies, including an AI model that improved healthcare provider directory accuracy. H1 serves 85% of top 20 pharma companies and 9 out of 10 top health plans, and is on track to achieve above Rule of 40 profitability metrics in 2026.

Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.

CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.